

What: Operations Committee Meeting  
 Date & Time: October 24, 2024; 12:30-1:30 p.m. PT  
 Location: Zoom

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

**Agenda**

Approx. Time	*	Page	Topic/[Anticipated Action]	Presented by:
12:30-12:35 p.m.			1. Introductions & Agenda Review a. Notice of Recording b. Survey of Other Topics	J. Zell
12:35-12:40 p.m.	*	Pg. 3-4	2. Action Items a. <b>Vote to Approve Operations Committee Minutes, April 25, 2024</b>	J. Zell
12:40-1:15 p.m.	* * *	Pg. 5 Pg. 6-12  Pg. 13-15	3. Operations Updates a. Non-traditional Provider Onboarding b. Future Assessment Grid a. Cash Reserves b. Investment Policy Statement c. New Vaccine Pipeline c. Future Grid Communications d. Cybersecurity e. EHR Vendor Collaboration	J. Zell / P. Miller
1:15-1:20 p.m.	*	Pg. 16	4. Other Matters from Committee Members a. April 24, 2025 – Next Operations Committee	J. Zell / P. Miller
1:20-1:25pm			5. Public Comment (if time permits)	J. Zell
1:25-1:30 p.m.			6. Closing	J. Zell

\*Indicates agenda item attached  
 Red text indicates an action item

**October 24, 2024**

**WVA Meeting of the Operations Committee**

**Proposed Form of Votes**

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

**Items under Agenda Section 2:**

VOTED: To approve April 25, 2024 meeting minutes.

[To approved April 25, 2024 meeting with the changes suggested at the meeting.]

**Washington Vaccine Association  
Operations Committee Meeting  
April 25, 2024; 12:30-1:30 p.m. PT**

**I. Attendance.** Participating in all or part of the meeting by telephone were the following individuals:

Members

Diana Baxter, Cambia  
Tracy Cardillo, Cigna  
Cathy Falanga, Aetna  
Valerie Oliver, Premera  
Kara Manley, United

Helms & Company, Inc.

Patrick Miller, MPH, Administrative Director  
Ashley Ithal, MPH, Project Support Leader  
Lisa White, JD, Customer and Financial Support  
Specialist  
Leslie Walker, CPA, Mason+Rich, PA

WVA

Julia Walter Zell, Esq., Executive Director, Chair  
Cheri Cagle, Stakeholder Liaison

Public Members

Erika Cliett, United  
Tiffany Conley, Regence  
Cheryl Rairigh, Regence  
Jackie Vincent, TRICARE PacMed

**II. Summary of Actions Taken and/or Recommended**

Actions Taken (votes adopted)

- i. To approve October 26, 2023 meeting minutes.
- ii. Vote to finalize the 2024-25 Assessment Grid.

**III. Minutes**

Welcome and Introductions

Ms. Zell called the meeting to order at 12:32 p.m., and provided a notice of recording for the purposes of the meeting minutes. She stated the recording will be deleted once the meeting minutes are approved

Consent Calendar

Ms. Zell asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

**VOTED: To approve October 26, 2023 meeting minutes.**

**IV. Assessment Grid 2024-2025**

Mr. Miller summarized the FY24-25 Vaccine Assessment Grid (“Grid”) model process, the FY24-25 administrative budget, and the FY24-25 Grid model assumptions and projections. He stated that the last step in the process is the Operations Committee’s review and adoption of the Grid. Mr. Miller highlighted the current efforts to onboard providers not currently submitting dosage-based assessments (DBA), and the FY25 vaccine additions, changes, and retired vaccines / biologics. Mr. Miller reviewed the cash model projections for the next three years with the recommendation to increase the Grid in FY24-25 and hold it steady for the following two years. Ms. Zell added information about reserve projections being based on current efforts. Mr. Miller reviewed the Grid with the Committee, detailing the various changes made to the Grid since last week. Discussion ensued and concluded with consensus of the presented FY24-25 administrative budget and Grid model assumptions.

Ms. Zell asked for a motion to approve the FY2024-25 Grid. Upon motion duly made and seconded, it was unanimously

**VOTED: To finalize the FY2024-25 Assessment Grid.**

**V. Operational Updates**

67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

Non-Traditional Provider Outreach and Engagement

Ms. Zell, Ms. Ithal, and Ms. Cagle detailed the current engagement efforts of non-traditional provider outreach efforts inclusive of Direct Care Practices (DCPs), School Based Health Clinics (SBHCs), Pharmacies and Mobile Clinics to understand current adoption rates of the WVA DBA process. Ms. Zell noted that Local Health Jurisdictions (LHJs) are exempted from following the DBA process. Ms. Ithal noted that the Washington Department of Health (DOH) has partnered with the WVA in outreach efforts to non-traditional organizations that the WVA have not yet heard from. Ms. Ithal noted that both providers and payers will be required to update their systems to support DBA submission and payment.

Inpatient Hospital DBA Update

Ms. Ithal detailed the status of outreach efforts to the hospital organizations to ensure their respective billing and adjudication systems can support the WVA DBA process no later than July 1, 2024. She noted that a test process and tracking resource has been created and will be shared with providers this week. Related, payers will be notified concurrently that test claims could be coming through from these providers. Mr. Miller also noted that as a result of the fall 2023 Inpatient Hospital Workgroup sessions that an Inpatient Hospital Assessment Billing Guidance document was produced and published. Additionally, both existing provider and payer billing guidance documents were updated. All three documents are available on the WVA’s website.

Vaccine Pipeline - Penbraya™

Mr. Miller stated that Penbraya™ will be added to the Grid as of June 1, 2024. Communications were sent last week to payers and providers by email and simultaneously posted on the WVA website.

**VI. Other Matters from Committee Members – None.**

**VII. Closing**

Ms. Zell concluded the meeting at 1:24pm.


## 3.a. Non-Traditional Provider Onboarding

1. Outpatient provider types include:
  - Direct Care Practices (DCPs)
  - Independent Pharmacies
  - Mobile Health Clinics
  - Local Health Jurisdictions (LHJs)
  - School Based Health Clinics (SBHCs)
  - Tribal
2. Exempt types include:
  - Tribal
  - LHJs are currently exempt, however, some are able to comply with the DBA
3. Work plan summary:
  - 151 Providers contacted
  - Work groups for LHJs and SBHCs held
  - Onboarding in process for those who can comply
  - Hospital compliance due July 1, 2024
  - OIC and DOH determining DCP strategy
  - November 7 WVA Board meeting recommendations adopted




# 3.b. Per Dose Trends


**WVA Remittance Per Dose, Non-Flu Dose, and Flu Dose  
FY2015-FY2024**



## 3.b. Recent Market Additions



# 3.b. RSV Nirsevimab & Influenza – A Tale of Two Immunizations





## 3.b. New Vaccine Pipeline

### 1. WVA is Focused On:

- Respiratory Vaccines (Influenza, COVID, RSV)
- mRNA Vaccines and Other New Technologies
- Combination Vaccines
- High Dollar High Volume


### 2. ACIP Meeting Held October 23 & 24

### 3. WVA and DOH Hold Quarterly Manufacturer Meetings





### 3.b. Cash Ending Balance – Actual and Projected (April 2024)



## 3.b. CY2023 and CY2024 Impacts on Cash Reserves

Item	Fiscal Impact*
2023 COVID-19 Purchases	\$10,058,512
2023 RSV Purchases (no DBAs received)	\$5,569,374
FY2024 Influenza Write-down	\$1,955,314
FY2024 COVID-19 Write-down	\$4,368,119
2024 Pre-Funding of Fall 2024 Influenza (prior to DBA receipt)	\$3,508,813
2024 Pre-Funding of Fall 2024 COVID-19 (prior to DBA receipt)	\$3,798,096
2024 Pre-Funding of Fall 2024 RSV (prior to DBA receipt)	\$5,530,000
<b>Total</b>	<b>\$34,788,288</b>

Notes:

- Some hospitals are still onboarding resulting in delayed payments.
- The fund source split set at 47% in January 2023 will be increased to 49% at some point in CY 2025. More information will be known when the WVA receives the November 2024 Projection Packet from the WA DOH.

## 3.b. Investment Policy Statement Update

“The WVA Board has determined that an unrestricted pool of reserve funds is necessary to ensure adequate availability of monies to meet the WVA’s statutory obligation to provide funds for the Washington Department of Health’s (DOH) purchase of pediatric vaccines for commercially insured children. This reserve is funded through dosage-based assessment (DBA) collections not immediately needed to fund vaccines and is intended to provide sufficient resources to prefund requests prior to the receipt of assessments. Additionally, the reserve funds are intended to provide stability to the WVA’s Assessment Grid over a multi-year period by providing a cushion to absorb the impact of new immunization products coming to market and the variability of funding requests due to seasonality. The WVA Board periodically determines appropriate reserve targets based upon, but not limited to, the following factors: 1) the total immunization budget, 2) monthly DOH and WVA vaccine projections, 3) expected periods of large funding requests due to seasonality, 4) expected new immunization products coming to market, 5) average cost of immunization products available through the program, 6) immunization product waste and unused immunization product, 7) prior and projected changes to the WVA’s Assessment Grid, 8) WVA administrative costs, and 9) investment returns.”

Revised and Restated 10.10.2024



# PAYER BULLETIN: PENBRAYA™

WASHINGTON VACCINE ASSOCIATION

**April 12, 2024**

**Dear WVA Payer:**

Effective **June 1, 2024**, the **PENBRAYA™** meningococcal groups A, B C, W, and Y vaccine for persons under the age of 19 will be added to the WVA’s [Vaccine Assessment Grid](#). Providers participating in the WA Department of Health’s Childhood Vaccine Program will be instructed to bill this code effective **June 1, 2024**.

**As a payer, you are required to update your adjudication system to include the following CPT code, two NDC codes, and WVA assessment amount to accurately reimburse the WVA for PENBRAYA™.**

**Update your fee schedules!**

NAME	CPT CODE	NDC CODE / PACKAGING	WVA ASSESSMENT AMOUNT
Penbraya™	90623	00069-0600-01 (1 Pack - Single Dose Vial)	\$207.67
		00069-0600-05 (5 Pack – Single Dose Vial)	

For more information regarding the DBA process, please see the [WVA Health Insurer and TPA Compliance Guide](#), [wavaccine.org](http://wavaccine.org), or [compliance@wavaccine.org](mailto:compliance@wavaccine.org).

Best regards,



Julia Walter Zell, MA, Esq., Executive Director



**WVA Tax ID: 27-2251833**  
**WVA NPI: 1699092718**

**IMPORTANT UPDATE - PLEASE READ**

September 9, 2024

**RE: NOVAVAX AND THE 2024-25 WVA VACCINE ASSESSMENT GRID**

**VIA EMAIL:** To Washington Vaccine Association Health Insurers and Third-Party Administrators,

Please note an update to the *2024-25 WVA Assessment Grid* (the "Grid") regarding the status of Novavax. **The following Novavax code has been updated by the Childhood Vaccine Program (CVP) effective for September 3, 2024 dates of service. PLEASE, UPDATE YOUR FEE SCHEDULE.** A similar notice has been sent to providers enrolled in the CVP.

Effective Date	Category	CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose from 07/01/2023 to 06/30/2024	WVA Assessment Amount per dose from 07/01/2024 to 06/30/2025
<b>September 3, 2024 to June 30, 2025</b>	<b>COVID-19</b>	<b>91304</b>	<b>80631-0107-10</b> <b>NEW: 9.03.2024</b> (10 pack - 1 dose syringe)	SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose	<b>COVID-19 Vaccine (Novavax) (ages 12+yrs)</b>	\$105.00	<b>\$113.00</b>

The enclosed *Grid* is in effect between July 1, 2024 through June 30, 2025, and is posted to the WVA's website in both PDF and Excel format (<https://wavaccine.org/assessment-grid/>).

As a reminder, the *Grid* lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third-party administrators (TPAs). In effect, the *Grid* is the equivalent to a fee schedule. Providers are required to submit the DBA at the *Grid* amount, and **health insurance carriers and TPAs are required to remit the full amount to the WVA.** Properly remitted and paid DBAs ensure that adequate funds are available to support the State's continued purchase of pediatric vaccines in Washington.

In addition to the *Grid*, please find enclosed the following WVA's *Health Insurers and Third-Party Administrators Compliance Guide*. This *Guide* contains a checklist of items to ensure compliance with the WVA's requirements.

Should you have any questions or if you are not the correct contact within your organization to receive this information, please notify us at [compliance@wavaccine.org](mailto:compliance@wavaccine.org). We appreciate your organization's support of the WVA.



*Ensuring Funds for Childhood Vaccines*

Best regards,

A handwritten signature in black ink, appearing to read 'Patrick Miller', is written over a light blue horizontal line.

Patrick Miller, MPH  
Administrative Director

Cc: Julia Zell, MA, Esq., Executive Director

Attachment:

- *WVA Vaccine Assessment Grid*
- *WVA's Health Insurers and Third-Party Administrators Compliance Guide*



**2025 WVA Corporate  
Governance Calendar**  
Board Meeting and Committee  
Meeting Schedules

<b>Month</b>	<b>Board Meeting 1:30-4 PM</b>	<b>Executive Committee 2:30-4 PM</b>	<b>Finance Committee 10:30-12 PM</b>	<b>Vaccine Committee 12-1 PM</b>	<b>Operations Committee 12:30-1:30 PM</b>
January		Jan 30	Jan 24 <i>10-12p meeting</i>		
February	February 13			February 6	
March					
April	Apr 17	Apr 10	Apr 10		Apr 24 Grid Approval
May					
June		Jun 5			
July	Jul 24 In Person <i>12:30p lunch 1-4p meeting</i>				
August		Aug 21			
September			Sep 18		
October		Oct 16			Oct 23
November	Nov 6 In Person <i>12:30p lunch 1-4p meeting</i>			Nov 13	
December		Dec 4			

**\*All times are Pacific Time**

- A written annual report may serve in lieu of an annual meeting of members. (Bylaws section 4.2)
- Officers are elected for 1-year terms at the annual meeting of the Board (Bylaws section 6.1)
- Committees may adjust their scheduled meeting dates or times for the convenience of their members

As of 10.17.2024